BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
BXCL501 met primary endpoint in agitated schizophrenia patients with clinically meaningful, rapid and durable reduction in PEC score maintained for 4 to 6 hours in its Phase 1b, randomized, double blind, placebo controlled clinical trial
On track to initiate BXCL501 Phase 3 pivotal trial in Q4 2019 in agitated schizophrenia and bipolar patients subject to discussion with U.S. FDA; data readout expected 1H 2020
BXCL501 Phase 1b trial in agitated Alzheimer’s disease/dementia patients expected to initiate in Q4 2019
BXCL701 has two ongoing Phase 1b/2 clinical trials in pancreatic cancer and treatment emergent neuroendocrine prostate cancer (tNEPC); data readouts expected in 2H 2019 and 1H 2020
BTI added to the Russell 2000® and 3000® Indexes
Conference call scheduled for August 6th at 8:30 AM ET
NEW HAVEN, Conn., Aug. 06, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced its quarterly results for the second quarter ended June 30, 2019 and provided an update on key strategic and operational initiatives. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.
Second Quarter 2019 and Recent Highlights
- BXCL501 adaptive Phase 1b, randomized, double blind, placebo-controlled, multi-center, U.S. trial reported positive topline data as a potential therapy for acute treatment of agitation in schizophrenia patients;
- BXCL501 met primary endpoint and demonstrated statistically significant and clinically meaningful rapid mean reduction in PEC (PANSS or the Positive and Negative Syndrome Scale, Excitatory Component) score at two hours compared to placebo following a single dose of 80 mcg (p=0.0152), 120 mcg (p=0.0003) and 180 mcg (p<0.0001);
- Results from secondary analyses showed statistically significant calming as measured by the ACES (Agitation-Calmness Evaluation Scale) at two hours compared to placebo following a single dose of 80 mcg (p=0.0156), 120 mcg (P=0.0005) and 180 mcg (P<0.0001);
- Well tolerated with no serious or severe adverse events across the entire dose range;
- Trial results support the potential to advance the BXCL501 program to Phase 3 pivotal studies in agitated schizophrenia and bipolar patients, subject to a pre-Phase 3 meeting with the FDA;
- Phase 3 Pivotal trials are anticipated to enroll approximately 600 to 700 patients (300-350 each in schizophrenia and bipolar disorder), designed to measure reduction in PEC at two hours as the primary endpoint, as used in clinical trials of other approved agents. A data readout is expected in 1H 2020;
- BXCL501 adaptive Phase 1b trial in agitated Alzheimer’s disease/dementia patients is expected to begin in Q4 2019;
- Development plans for the acute treatment of agitation with BXCL501 in hyperactive delirium and opioid withdrawal are underway
- Currently enrolling patients in the U.S. in the double combination of BXCL701 and Keytruda® clinical trial for treatment emergent Neuroendocrine Prostate Cancer (tNEPC). Multiple patients have been treated in the safety and escalation portion of the trial which will be followed by a two-stage efficacy portion of the clinical program. A data read out is expected in 2H 2019;
- Clinical Trial Application (CTA) was accepted by the U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”) for the double combination trial of BXCL701 and Keytruda® in tNEPC patients. Expected to activate clinical sites, subject to approval from local U.K. authorities. This approval is the first step in our plan to expand our clinical trials globally;
- FDA authorized the IND application for the triple combination of BXCL701, bempegaldesleukin (produced by Nektar Therapeutics, Inc., or Nektar) and BAVENCIO® (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer. The safety escalation portion of the trial is ongoing and will be followed by a two-stage efficacy portion. A data read-out is expected in 1H 2020;
- Pursuing a clinical proof of mechanism study with BXCL701 in pancreatic cancer patients to characterize immune cell infiltration and activation and the circulating cytokines elicited in order to validate it’s mechanism of action;
- Continuing to explore additional indications for BXCL701 with synergistic combinations
“We are excited by the clinical achievements we made during this quarter by advancing both our lead neuroscience program, BXCL501, and our immuno-oncology program, BXCL701,” commented Vimal Mehta, President and Chief Executive Officer of BTI.
“In our BXCL501 program, we recently announced positive top-line data from our adaptive Phase 1b, randomized, double-blind, placebo-controlled, multi-center, U.S. trial demonstrating statistically significant reductions in the PEC score at two hours compared to placebo for multiple dosages and displayed rapid and durable calming effect without excessive sedation for such dosages. The drug was also well tolerated across all doses tested. We are pleased by these results which reflect significant progress in developing a non-invasive, easy to administer therapy, and which provide evidence supporting BXCL501’s potential as a rapid-onset treatment for acute agitation. Based on these results, we intend to have discussions with the FDA to determine the path forward for the BXCL501 program. We anticipate moving into the pivotal Phase 3 trial in the fourth quarter of 2019 and expect a data readout during the first half of 2020. Additionally, we are also planning to begin a Phase 1b trial in agitated Alzheimer’s disease/dementia patients that we expect to initiate in the fourth quarter of 2019. With all these positive developments, we remain confident in our strategic plan to submit our first NDA for BXCL501 during the second half of 2020.”
Dr. Mehta added, “We are also committed to driving progress in our immuno-oncology program for BXCL701 with two ongoing Phase 1b/2 trials. We are evaluating the combination of BXCL701 and Keytruda® in tNEPC, an aggressive form of prostate cancer with limited treatment options. We are enrolling patients in this Phase 1b/2 study of BXCL701 combined with Keytruda® in the United States, and multiple patients have been treated in the safety and escalation portion of the trial. A data readout for this study is anticipated in the second half of 2019. Further, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) accepted our clinical trial authorization to evaluate BXCL701 plus Keytruda® in tNEPC which allows us to expand the development of this double combination into other geographies. Following the FDA authorization of our IND application for the combination of BXCL701, bempegaldesleukin and BAVENCIO® as a second line therapy for pancreatic cancer, we initiated a clinical study for which data readouts are expected in the first half of 2020. Our collaboration with Nektar Therapeutics, Merck KGaA, Darmstadt, Germany and Pfizer enables us to pursue our mutual goal of advancing the triple combination of immuno-oncology agents in pancreatic cancer to bring an effective therapeutic option in this large, underserved indication.”
“With the achievement of these value driving milestones in both of our lead programs, we are extremely pleased with our performance during the second quarter. We also raised our visibility in the financial community through BTI’s addition to the Russell 2000® and 3000® Indexes. As we continue to effectively manage our cash position, we believe it will be sufficient to fund key milestones and operations to mid-2020. We remain confident in our strategy and believe we are positioned for continued growth.”
Second Quarter 2019 Financial Results
BTI reported a net loss of $8.5 million for the second quarter of 2019, compared to a net loss of $3.0 million for the same period in 2018.
Research and development expenses were $6.5 million for the second quarter of 2019, as compared to $1.8 million for the same period in 2018. The increase was primarily due to an expansion of research and development activities, including increased personnel costs, clinical trials expenses, manufacturing costs, and professional fees, associated with BTI’s two lead product candidates.
General and administrative expenses were $2.1 million for the second quarter of 2019, as compared to $1.5 million for the same period in 2018. The increase was primarily due to additional payroll and payroll-related expenses, professional fees and costs associated with operating as a public company.
These results include approximately $1.0 million in non-cash stock based compensation.
As of June 30, 2019, cash and cash equivalents totaled approximately $30.0 million. BTI is well positioned to execute on key milestones with sufficient cash to fund operations through mid-2020.
BTI will host a conference call and webcast today at 8:30 a.m. ET. To access the call please dial (800) 239-9838 (domestic) and (323) 994-2093 (international) and provide the passcode 2198753. A live webcast of the call will be available on the Investors sections of the BTI website at www.bioxceltherapeutics.com. The archived webcast will be available through September 6, 2019.
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 is currently being developed for agitation associated with schizophrenia and bi-polar disorders followed by Alzheimer's/dementia.
BXCL701 is an investigational orally-available systemic innate immunity activator with dual mechanisms of action. It has demonstrated single agent activity in melanoma and safety has been evaluated in more than 700 healthy subjects and cancer patients. Designed to stimulate both the innate and acquired immune systems, BXCL701 inhibits dipeptidyl peptidase (DPP) 8/9 and blocks immune evasion by targeting Fibroblast Activation Protein (FAP). BXCL701, is currently being developed for treatment of a rare form of prostate cancer and for pancreatic cancer in combination with other immuno-oncology agents
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, the Company’s the timing and data from clinical development initiatives and trials for BXCL501 and BXCL701, the Company’s discussions with the FDA, the Company’s future growth and the Company’s available funding through mid-2020. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.
These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release.
BioXcel Therapeutics, Inc.
The Ruth Group
BIOXCEL THERAPEUTICS, INC.
(amounts in thousands, except share and per share data)
|June 30,||December 31,|
|Cash and cash equivalents||$||29,965||$||42,565|
|Prepaid expenses and other current assets||1,500||491|
|Due from Parent||46||115|
|Total current assets||31,511||43,171|
|Deferred offering expenses||378||—|
|Property and equipment, net||1,092||327|
|Operating lease right-of-use asset||1,246||—|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other current liabilities||659||—|
|Total current liabilities||8,009||4,660|
|Operating lease liability||1,112||—|
|Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or outstanding||—||—|
|Common stock, $0.001 par value, 50,000,000 shares authorized; 15,687,546 and
15,663,221 shares issued and outstanding as of June 30, 2019 and December 31, 2018,
|Total stockholders' equity||25,157||38,889|
|Total liabilities and stockholders' equity||$||34,278||$||43,549|
BIOXCEL THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
|Three Months Ended June 30,||Six Months Ended June 30,|
|Operating costs and expenses|
|Research and development||6,506||1,781||12,180||4,719|
|General and administrative||2,129||1,463||3,874||2,811|
|Total operating expenses||8,635||3,244||16,054||7,530|
|Loss from operations||(8,635||)||(3,244||)||(16,054||)||(7,530||)|
|Dividend and interest income, net||164||218||379||222|
|Net loss per share attributable to common
stockholders basic and diluted
|Weighted average shares outstanding - basic and
BIOXCEL THERAPEUTICS, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY / DEFICIT
(amounts in thousands, except shares)
|Common Stock||Paid in||Accumulated|
|Balance as of December 31, 2017||9,907,548||$||10||$||3,458||$||(4,450||)||$||(982||)|
|Issuance of common shares||283,452||1||1,949||—||1,950|
|Issuance of common shares, upon completion of Initial Public Offering, net of issuance costs of $5,898||5,454,545||5||54,097||—||54,102|
|Balance as of March 31, 2018||15,645,545||$||16||$||60,823||$||(8,732||)||$||52,107|
|Balance as of June 30, 2018||15,645,545||$||16||$||61,563||$||(11,758||)||$||49,821|
|Balance as of December 31, 2018||15,663,221||$||16||$||62,593||$||(23,720||)||$||38,889|
|Exercise of stock options||2,581||—||1||—||1|
|Balance as of March 31, 2019||15,665,802||$||16||$||63,276||$||(30,924||)||$||32,368|
|Issuance of common shares||21,744||—||230||—||230|
|Balance as of June 30, 2019||15,687,546||$||16||$||64,536||$||(39,395||)||$||25,157|
BIOXCEL THERAPEUTICS, INC.
STATEMENTS OF CASH FLOWS
(amounts in thousands)
|Six months ended June 30,|
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Reconciliation of net loss to net cash used in operating activities|
|Depreciation and amortization||122||2|
|Stock-based compensation expense||1,712||2,059|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||(1,009||)||(666||)|
|Accounts payable, accrued expenses and other||3,153||(69||)|
|Net cash used in operating activities||(11,697||)||(5,982||)|
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Purchases of equipment and leasehold improvements||(825||)||(120||)|
|Net cash used in investing activities||(825||)||(120||)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Proceeds from issuance of common stock, net||230||56,512|
|Deferred offering costs||(378||)||—|
|Exercise of options||1||—|
|Due to/from Parent||69||(577||)|
|Note Payable — Parent||—||(371||)|
|Net cash (used in) provided by financing activities||(78||)||55,564|
|Net (decrease) increase in cash and cash equivalents||(12,600||)||49,462|
|Cash and cash equivalents, beginning of the period||42,565||887|
|Cash and cash equivalents, end of the period||$||29,965||$||50,349|
|Supplemental cash flow information:|
|Supplemental disclosure of non-cash Financing Activity:|
|Deferred issuance costs, unpaid as of December 31, 2017||$||—||$||391|
|Deferred issuance costs reclassified to additional paid-in-capital upon completion of initial public offering.||$||—||$||461|
|Reclassification of net Parent Investment in the Company to accumulated deficit.||$||—||$||440|
Released August 6, 2019